In March 2025, the company declared new strategies for a direct-to-consumer supplying of its Wegovy weight loss drug. The company recognized a whole new pharmacy, called NovoCare, which would cost consumers $499 every month for entry to the drug, less than half the expense of the drug through other pharmaceutical distribution networks.[53]This led